Clinical Trials in North Carolina

Showing 4081-4100 of 17,526 trials

Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

NCT05369000

This is a phase 1, first-in-human study to evaluate Safety, Tolerability, PK, PD, Immunogenicity, and Antitumor Activity of LAVA-1207 alone or with low dose interleukin-2 or Pembrolizumab, in patients with therapy refractory metastatic castration resistant prostate cancer.

Metastatic Castration Resistant Prostate Cancer

Lava Therapeutics96 participantsStarted Jan 2022

San Francisco, California, United States • Minneapolis, Minnesota, United States • St Louis, Missouri, United States +9 more locations

TERMINATEDPhase 1/260 miles

MGC018 With or Without MGA012 in Advanced Solid Tumors

NCT03729596

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors. Patients with solid tumors will be enrolled in the Dose Escalation Phase; Cohort Expansion will include metastatic castrate-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), and melanoma. Patients who do not experience unacceptable toxicity or meet criteria for permanent discontinuation may undergo additional cycles for up to two years. Patients in Cohort Expansion will be followed for survival every 3 months for 2 years following last dose.

Squamous Cell Carcinoma of Head and NeckTriple Negative Breast CancerMelanoma+3 more

MacroGenics143 participantsStarted Nov 2018

Santa Monica, California, United States • Washington D.C., District of Columbia, United States • Baltimore, Maryland, United States +18 more locations

Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

MGC018 With or Without MGA012 in Advanced Solid Tumors

Find Trials by Condition in North Carolina

Study of SGR-3515 In Participants With Advanced Solid Tumors.

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

Transorb™ Self-Gripping Resorbable Mesh in High-risk Subjects Undergoing Open Repair of Ventral Hernia

Portico Next Generation Approval Study

Otitis Treatment With OtoSight™ - Modification of Antibiotic Treatment Intervention in Children

A Study in Adults and Adolescents With Angelman Syndrome (STARS)

MYTHS - MYocarditis THerapy With Steroids

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)

RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).

AI-Powered Artificial Vision for Visual Prostheses